PT2981279T - Péptidos inibidores de marcks para inibir metástases - Google Patents

Péptidos inibidores de marcks para inibir metástases

Info

Publication number
PT2981279T
PT2981279T PT14779844T PT14779844T PT2981279T PT 2981279 T PT2981279 T PT 2981279T PT 14779844 T PT14779844 T PT 14779844T PT 14779844 T PT14779844 T PT 14779844T PT 2981279 T PT2981279 T PT 2981279T
Authority
PT
Portugal
Prior art keywords
inhibitor peptides
inhibiting metastasis
marcks
marcks inhibitor
metastasis
Prior art date
Application number
PT14779844T
Other languages
English (en)
Portuguese (pt)
Inventor
Parikh Indu
B Adler Kenneth
Original Assignee
Univ North Carolina State
Biomarck Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State, Biomarck Pharmaceuticals Ltd filed Critical Univ North Carolina State
Publication of PT2981279T publication Critical patent/PT2981279T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10Peptides having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
PT14779844T 2013-04-05 2014-04-07 Péptidos inibidores de marcks para inibir metástases PT2981279T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361808966P 2013-04-05 2013-04-05

Publications (1)

Publication Number Publication Date
PT2981279T true PT2981279T (pt) 2019-03-14

Family

ID=51654619

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14779844T PT2981279T (pt) 2013-04-05 2014-04-07 Péptidos inibidores de marcks para inibir metástases

Country Status (19)

Country Link
US (4) US9408886B2 (cg-RX-API-DMAC7.html)
EP (1) EP2981279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6449849B2 (cg-RX-API-DMAC7.html)
KR (1) KR102191695B1 (cg-RX-API-DMAC7.html)
CN (1) CN105517562B (cg-RX-API-DMAC7.html)
AU (1) AU2014247979B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015025398A2 (cg-RX-API-DMAC7.html)
CA (1) CA2908832C (cg-RX-API-DMAC7.html)
DK (1) DK2981279T3 (cg-RX-API-DMAC7.html)
ES (1) ES2714863T3 (cg-RX-API-DMAC7.html)
HU (1) HUE043971T2 (cg-RX-API-DMAC7.html)
IL (1) IL241937B (cg-RX-API-DMAC7.html)
MX (1) MX363077B (cg-RX-API-DMAC7.html)
PL (1) PL2981279T3 (cg-RX-API-DMAC7.html)
PT (1) PT2981279T (cg-RX-API-DMAC7.html)
RU (1) RU2681213C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201708125PA (cg-RX-API-DMAC7.html)
WO (1) WO2014165853A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201508010B (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования
CN108686220A (zh) * 2018-07-13 2018-10-23 刘慧荣 一种针对甲状腺癌的抗肿瘤剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US7265088B1 (en) 2000-02-24 2007-09-04 North Carolina State University Method and compositions for altering mucus secretion
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
AU2002362753B9 (en) * 2001-10-05 2008-05-15 The Trustees Of The University Of Pennsylvania Compositions for and methods of treating and preventing sirs/sepsis
DE60308251T2 (de) 2002-04-17 2007-08-30 Canon K.K. Vorrichtung zur Bereitstellung von öffentlichen Schlüsselzertifikaten
US7524926B2 (en) 2005-01-20 2009-04-28 Biomarck Pharmaceuticals, Ltd. Mucin hypersecretion inhibitors and methods of use
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
PT2053915E (pt) * 2006-07-26 2014-08-25 Biomarck Pharmaceuticals Ltd Peptídeos para atenuar a libertação de mediadores inflamatórios
EP2069477A4 (en) 2006-10-06 2010-12-08 Celtaxsys Inc CHEMICAL REPULSION OF CELLS
EP2078204A2 (en) * 2006-10-27 2009-07-15 George Mason Intellectual Properties, Inc. Assay for metastatic colorectal cancer
WO2009062128A2 (en) * 2007-11-08 2009-05-14 Indiana University Research And Technology Corporation Combination drug therapy for the treatment of cancer
EP2105511A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
US9073974B2 (en) * 2009-12-21 2015-07-07 The Regents Of The University Of California RGD-containing cyclic peptides
JP6225104B2 (ja) * 2011-04-08 2017-11-01 タフツ メディカル センター インコーポレイテッドTufts Medical Center,Inc. ペプデューシンの設計および使用
RU2681213C2 (ru) 2013-04-05 2019-03-05 Байомарк Фармасьютикалз, Лтд. Ингибиторы метастазирования

Also Published As

Publication number Publication date
RU2015146997A (ru) 2017-05-15
CA2908832A1 (en) 2014-10-09
AU2014247979A1 (en) 2015-10-29
EP2981279A4 (en) 2016-11-09
ES2714863T3 (es) 2019-05-30
MX363077B (es) 2019-03-07
KR20150140736A (ko) 2015-12-16
US9408886B2 (en) 2016-08-09
JP6449849B2 (ja) 2019-01-09
SG10201708125PA (en) 2017-11-29
CN105517562B (zh) 2018-12-28
ZA201508010B (en) 2017-01-25
RU2015146997A3 (cg-RX-API-DMAC7.html) 2018-03-13
US20210130403A1 (en) 2021-05-06
WO2014165853A1 (en) 2014-10-09
AU2014247979B2 (en) 2018-06-28
US11466054B2 (en) 2022-10-11
US20140302057A1 (en) 2014-10-09
NZ712955A (en) 2021-03-26
US20190119320A1 (en) 2019-04-25
PL2981279T3 (pl) 2019-09-30
HUE043971T2 (hu) 2019-09-30
EP2981279A1 (en) 2016-02-10
JP2016516756A (ja) 2016-06-09
KR102191695B1 (ko) 2020-12-16
CN105517562A (zh) 2016-04-20
EP2981279B1 (en) 2018-12-19
US10683328B2 (en) 2020-06-16
MX2015014036A (es) 2016-02-25
IL241937B (en) 2019-03-31
BR112015025398A2 (pt) 2017-10-10
HK1221159A1 (en) 2017-05-26
DK2981279T3 (en) 2019-03-25
US10011636B2 (en) 2018-07-03
US20170121369A1 (en) 2017-05-04
RU2681213C2 (ru) 2019-03-05
SG11201508249WA (en) 2015-11-27
CA2908832C (en) 2023-01-24

Similar Documents

Publication Publication Date Title
ZA201800913B (en) Syk inhibitors
IL243578A0 (en) syk inhibitors
ZA201506796B (en) Ido inhibitors
IL242005B (en) A peptide compound
IL240962B (en) cdc7 inhibitors
IL239827A0 (en) Deoxyuridine triphosphatase inhibitors
ZA201506156B (en) Novel inhibitors
ZA201506516B (en) Hdac inhibitors
GB201317609D0 (en) Inhibitor compounds
SG11201602091VA (en) Amidoamine gas hydrate inhibitors
SG11201509650YA (en) Slc2a transporter inhibitors
PT2981279T (pt) Péptidos inibidores de marcks para inibir metástases
GB201318182D0 (en) Inhibitor peptides
GB201321328D0 (en) Inhibitor compounds
GB201305503D0 (en) Inhibitor
GB201307906D0 (en) Corrosion inhibitor
GB201320835D0 (en) HIF inhibitors